The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short

Viking Therapeutics, Inc. faces significant challenges with VK2735, lacking differentiation from established obesity treatments like ZEPBOUND and WEGOVY. Phase 2 data highlight tolerability issues at higher VK2735 doses, suggesting real-world efficacy may be limited by discontinuation rates. Viking's induction-maintenance strategy appears reactive, with competitors like Amgen and Pfizer advancing superior, longer-acting regimens.

Seeking Alpha • Feb 5, 2026

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time  SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026.

PRNewsWire • Feb 4, 2026

The Smartest Growth Stock to Buy With $30 Right Now

The recent success of Novo Nordisk and Eli Lilly validates a potential $150 billion obesity drug market. Viking Therapeutics is a year or two from launching a drug that can compete with industry leaders.

The Motley Fool • Feb 3, 2026

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market.

Reuters • Feb 3, 2026

Viking Therapeutics to Report Q4 Earnings: Here's What to Know

VKTX heads into Q4 earnings with investor focus on VK2735's late-stage obesity studies that are witnessing rapid enrollment momentum.

Zacks Investment Research • Jan 30, 2026

Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $29.06, signifying a -3.9% move from its prior day's close.

Zacks Investment Research • Jan 30, 2026

2 Biotech Stocks Set to Rebound in 2026

Following recent challenges, these drugmakers could see solid clinical progress in the next 12 to 18 months. Both could launch products with significant sales potential and ride that wave through the medium term.

The Motley Fool • Jan 27, 2026

Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?

NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.

Zacks Investment Research • Jan 27, 2026

Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?

Eli Lilly and Viking Therapeutics both operate in the high-growth field of obesity drugs. This market is forecast to reach almost $100 billion by the end of the decade.

The Motley Fool • Jan 26, 2026

The Best Stocks to Invest $40 in to Start the New Year Off Right

Pfizer's deep pipeline could prove its greatest asset, helping it bounce back. Viking Therapeutics is developing a highly promising weight loss medicine.

The Motley Fool • Jan 24, 2026